The DOI matches its Crossref record; 37 of the 39 references it cites were found in a registry or an index.
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
Abstract
Background The anti-CD52 monoclonal antibody alemtuzumab reduced disease activity in a phase 2 trial of previously untreated patients with relapsing-remitting multiple sclerosis. We aimed to assess efficacy and safety of first-line alemtuzumab compared with interferon beta 1a in a phase 3 trial.Methods In our 2 year, rater-masked, randomised controlled phase 3 trial, we enrolled adults aged 18-50 years with previously untreated relapsing-remitting multiple sclerosis. Eligible participants were randomly allocated in a 2:1 ratio by an interactive voice response system, stratified by site, to receive intravenous alemtuzumab 12 mg per day or subcutaneous interferon beta 1a 44 μg. Interferon beta 1a was given three-times per week and alemtuzumab was given once per day for 5 days at baseline and once per day for 3 days at 12 months. Coprimary endpoints were relapse rate and time to 6 month sustained accumulation of disability in all patients who received at least one dose of study drug. This study is registered with ClinicalTrials.gov, number NCT00530348.Findings 187 (96%) of 195 patients randomly allocated interferon beta 1a and 376 (97%) of 386 patients randomly allocated alemtuzumab were included in the primary analyses. 75 (40%) patients in the interferon beta 1a group relapsed (122 events) compared with 82 (22%) patients in the alemtuzumab group (119 events; rate ratio 0·45 [95% CI 0·32-0·63]; p<0.0001), corresponding to a 54·9% improvement with alemtuzumab. Based on Kaplan-Meier estimates, 59% of patients in the interferon beta 1a group were relapse-free at 2 years compared with 78% of patients in the alemtuzumab group (p<0·0001). 20 (11%) of patients in the interferon beta 1a group had sustained accumulation of disability compared with 30 (8%) in the alemtuzumab group (hazard ratio 0·70 [95% CI 0·40-1·23]; p=0·22). 338 (90%) of patients in the alemtuzumab group had infusion-associated reactions; 12 (3%) of which were regarded as serious. Infections, predominantly of mild or moderate severity, occurred in 253 (67%) patients treated with alemtuzumab versus 85 (45%) patients treated with interferon beta 1a. 62 (16%) patients treated with alemtuzumab had herpes infections (predominantly cutaneous) compared with three (2%) patients treated with interferon beta 1a. By 24 months, 68 (18%) patients in the alemtuzumab group had thyroid-associated adverse events compared with 12 (6%) in the interferon beta 1a group, and three (1%) had immune thrombocytopenia compared with none in the interferon beta 1a group. Two patients in the alemtuzumab group developed thyroid papillary carcinoma.Interpretation Alemtuzumab's consistent safety profile and benefit in terms of reductions of relapse support its use for patients with previously untreated relapsing-remitting multiple sclerosis; however, benefit in terms of disability endpoints noted in previous trials was not observed here.Funding Genzyme (Sanofi) and Bayer Schering Pharma.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the phase III clinical trials comparing alemtuzumab with interferon β-1a in highly active MS, no overall increase in malignancy was observed;”
From 2019 European Thyroid Association Guidelines on the Management of Thyroid Dysfunction following Immune Reconstitution Therapy (2019) · cites this paper as [60]
In the citing paper
“however, papillary thyroid cancer was discovered in 0.4% of alemtuzumab-treated patients [59, 60].”
From 2019 European Thyroid Association Guidelines on the Management of Thyroid Dysfunction following Immune Reconstitution Therapy (2019) · cites this paper as [60]
Citations
Cites
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
Kurtzke, J. F. (1983) · Neurology · doi:10.1212/wnl.33.11.1444 · Cited by 15,011
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”
Polman, C. H., Reingold, S. C., Edan, G., Filippi, M., Hartung, H., Kappos, L., Lublin, F. D., Metz, L. M., McFarland, H. F., O'Connor, P. W., et al. (2005) · Annals of Neurology · doi:10.1002/ana.20703 · Cited by 5,017
Self-citationThe Robust Inference for the Cox Proportional Hazards Model
Lin, D. Y., & Wei, L. J. (1989) · Journal of the American Statistical Association · doi:10.1080/01621459.1989.10478874 · Cited by 2,695
Multiple Comparison Procedures
Hochberg, Y., & Tamhane, A. C. (1987) · Wiley Series in Probability and Statistics · doi:10.1002/9780470316672 · Cited by 2,389
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
Cohen, J. A., Barkhof, F., Comı, G., Hartung, H., Khatri, B. O., Montalbán, X., Pelletier, J., Capra, R., Gallo, P., Izquierdo, G., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907839 · Cited by 2,220
Self-citationMultiple Comparison Procedures
Hahs-Vaughn, D., & Lomax, R. (2013) · Routledge eBooks · doi:10.4324/9780203137819-17 · Cited by 2,132
Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis
Rudick, R. A., Stuart, W. H., Calabresi, P. A., Confavreux, C., Galetta, S. L., Radue, E. W., LUBLIN, F. D., Weinstock‐Guttman, B., Wynn, D. R., Lynn, F., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa044396 · Cited by 1,342
Self-citationDiagnostic criteria for multiple sclerosis
Poser, C. M., & Brinar, V. V. (2001) · Clinical Neurology and Neurosurgery · doi:10.1016/s0303-8467(00)00125-6 · Cited by 1,282
Self-citationColes, A. J., Twyman, C. L., Arnold, D. L., Cohen, J. A., Confavreux, C., Fox, E. J., Hartung, H.-P., Havrdova, E., Selmaj, K. W., Weiner, H. L., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61768-1 · Cited by 1,198
Self-citationDevelopment of a multiple sclerosis functional composite as a clinical trial outcome measure
Cutter, G. (1999) · Brain · doi:10.1093/brain/122.5.871 · Cited by 1,191
Cited by
Sorted by citations
Items 201–300 of 1,000
Marrie, R. A., Reider, N., Stüve, O., Trojano, M., Sørensen, P. S., Cutter, G., Reingold, S. C., & Cohen, J. A. (2014) · Multiple Sclerosis Journal · doi:10.1177/1352458514564488 · Cited by 57
Self-citationKappos, L., Arnold, D. L., Bar‐Or, A., Camm, A. J., Derfuss, T. J., Kieseier, B. C., Sprenger, T., Greenough, K., Ni, P., & Harada, T. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30192-2 · Cited by 57
Self-citationCorticosteroids in the management of acute multiple sclerosis exacerbations
On behalf of the Belgian Study Group for Multiple Sclerosis, Smets, I., Deun, L. V., Bohyn, C., Pesch, V. V., Vanopdenbosch, L. J., Dive, D., Bissay, V., & Dubois, B. (2017) · Acta Neurologica Belgica · doi:10.1007/s13760-017-0772-0 · Cited by 57
Cancer Incidence and Mortality Rates in Multiple Sclerosis
Marrie, R. A., Maxwell, C. J., Mahar, A. L., Ekuma, O., McClintock, C., Seitz, D. P., Webber, C., & Groome, P. A. (2020) · Neurology · doi:10.1212/wnl.0000000000011219 · Cited by 59
Management of infusion-related reactions in cancer therapy: strategies and challenges
Barroso, A., Estevinho, F., Hespanhol, V. P., Teixeira, E., Ramalho-Carvalho, J., & Araújo, A. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.102922 · Cited by 63
Reprogramming the immune repertoire with alemtuzumab in MS
Wiendl, H., & Kieseier, B. C. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2013.2 · Cited by 56
Drugs in Development for Relapsing Multiple Sclerosis
Ali, R., Nicholas, R. S., & Muraro, P. A. (2013) · Drugs · doi:10.1007/s40265-013-0030-6 · Cited by 58
Accelerated lymphocyte recovery after alemtuzumab does not predict multiple sclerosis activity
Kousin‐Ezewu, O., Azzopardi, L., Parker, R. A., Tuohy, O., Compston, A., Coles, A. J., & Jones, J. (2014) · Neurology · doi:10.1212/wnl.0000000000000520 · Cited by 56
Self-citationUpdate on Disease-Modifying Treatments for Multiple Sclerosis
Carrithers, M. D. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.08.006 · Cited by 55
The Diversity of Encephalitogenic CD4+ T Cells in Multiple Sclerosis and Its Animal Models
Segal, B. M. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8010120 · Cited by 60
Immune status following alemtuzumab treatment in human CD52 transgenic mice
Turner, M. J., LaMorte, M. J., Chrétien, N., Havari, E., Roberts, B., Kaplan, J. M., & Siders, W. (2013) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2013.04.018 · Cited by 54
Prosperini, L., Annovazzi, P. O. L., Boffa, L., Buscarinu, M. C., Gallo, A., Matta, M., Moiola, L., Musu, L., Perini, P., Avolio, C., et al. (2018) · Journal of Neurology · doi:10.1007/s00415-018-9070-x · Cited by 55
Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis
Barkhof, F., Kappos, L., Wolinsky, J. S., Li, D. K. B., Bar‐Or, A., Hartung, H., Belachew, S. M., Han, J., Julian, L. J., Sauter, A., et al. (2019) · Neurology · doi:10.1212/wnl.0000000000008189 · Cited by 56
Self-citationvon Kutzleben, S., Pryce, G., Giovannoni, G., & Baker, D. (2016) · Immunology · doi:10.1111/imm.12696 · Cited by 54
Self-citationComorbidity and Disease Activity in Multiple Sclerosis
Salter, A. R., Lancia, S., Kowalec, K., Fitzgerald, K. C., & Marrie, R. A. (2024) · JAMA Neurology · doi:10.1001/jamaneurol.2024.2920 · Cited by 59
Isidoro, L., Pires, P., Rito, L., & Cordeiro, G. (2014) · BMJ Case Reports · doi:10.1136/bcr-2013-201781 · Cited by 54
Alemtuzumab for Multiple Sclerosis
Willis, M., & Robertson, N. P. (2016) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-016-0685-y · Cited by 54
Learning from other autoimmunities to understand targeting of B cells to control multiple sclerosis
Baker, D., Pryce, G., Amor, S., Giovannoni, G., & Schmierer, K. (2018) · Brain · doi:10.1093/brain/awy239 · Cited by 54
Self-citationLong-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223
Steingo, B., Malik, Y. M. A., Bass, A. D.-D., Berkovich, R., Carraro, M., Fernández, Ó., Ionete, C., Massacesi, L., Meuth, S. G., Mitsikostas, D. D., et al. (2020) · Journal of Neurology · doi:10.1007/s00415-020-09983-1 · Cited by 54
Self-citationThe role of B cells in the immunopathogenesis of multiple sclerosis
Gharibi, T., Babaloo, Z., Hosseini, A., Marofi, F., Kalan, A. E., Jahandideh, S., & Baradaran, B. (2020) · Immunology · doi:10.1111/imm.13198 · Cited by 58
Monoclonal antibodies in treatment of multiple sclerosis
Rommer, P. S., Dudešek, A., Stüve, O., & Zettl, U. (2013) · Clinical & Experimental Immunology · doi:10.1111/cei.12197 · Cited by 53
Treating multiple sclerosis with monoclonal antibodies: a 2013 update
Deiß, A., Brecht, I., Haarmann, A., & Buttmann, M. (2013) · Expert Review of Neurotherapeutics · doi:10.1586/ern.13.17 · Cited by 53
Gilmore, W., Lund, B. T., Li, P., Levy, A. M., Kelland, E. E., Akbari, O., Groshen, S. G., Cen, S., Pelletier, D., Weiner, L. P., et al. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01847-9 · Cited by 52
Safety of Newer Disease Modifying Therapies in Multiple Sclerosis
Jalkh, G., Nahed, R. A., Macaron, G., & Rensel, M. R. (2020) · Vaccines · doi:10.3390/vaccines9010012 · Cited by 55
Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management
Cuker, A. C., Bass, A. D.-D., Nadj, Č., Agius, M. A., Steingo, B., Selmaj, K. W., Thoits, T., Guerreiro, A., Wijmeersch, B. V., Ziemssen, T., et al. (2019) · Multiple Sclerosis Journal · doi:10.1177/1352458518816612 · Cited by 52
Self-citationFischer, S., Proschmann, U., Akgün, K., & Ziemssen, T. (2021) · Cells · doi:10.3390/cells10113177 · Cited by 56
Alemtuzumab-induced immune phenotype and repertoire changes: implications for secondary autoimmunity
Ruck, T., Barman, S., Schulte‐Mecklenbeck, A., Pfeuffer, S., Steffen, F., Nelke, C., Schroeter, C. B., Willison, A., Heming, M., Müntefering, T., et al. (2022) · Brain · doi:10.1093/brain/awac064 · Cited by 52
Alemtuzumab use in neuromyelitis optica spectrum disorders: a brief case series
Azzopardi, L., Cox, A. L., McCarthy, C., Jones, J., & Coles, A. J. (2015) · Journal of Neurology · doi:10.1007/s00415-015-7925-y · Cited by 52
Self-citationBiolato, M., Bianco, A. D., Lucchini, M., Gasbarrini, A., Massimiliano Mirabella, A., & Grieco, A. (2021) · CNS Drugs · doi:10.1007/s40263-021-00842-9 · Cited by 52
Natalizumab: A Review of Its Use in the Management of Relapsing-Remitting Multiple Sclerosis
McCormack, P. L. (2013) · Drugs · doi:10.1007/s40265-013-0102-7 · Cited by 55
Hypothalamic Dysfunction and Multiple Sclerosis: Implications for Fatigue and Weight Dysregulation
Burfeind, K. G., Yadav, V., & Marks, D. L. (2016) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-016-0700-3 · Cited by 54
Active CMV infection in two patients with multiple sclerosis treated with alemtuzumab
Clerico, M., Mercanti, S. F. D., Artusi, C. A., Durelli, L., & Naismith, R. T. (2017) · Multiple Sclerosis Journal · doi:10.1177/1352458516688350 · Cited by 51
Yano, H., Gonzalez, C. T., Healy, B. C., Glanz, B. I., Weiner, H. L., & Chitnis, T. (2019) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2019.07.021 · Cited by 53
Self-citationDisease-Modifying Therapies in Multiple Sclerosis: Overview and Treatment Considerations.
Robertson, D. S., & Moreo, N. (2016) · Europe PMC (PubMed Central) · Cited by 50
Menge, T., Stüve, O., Kieseier, B. C., & Hartung, H.-P. (2014) · Neurology · doi:10.1212/wnl.0000000000000540 · Cited by 50
Self-citationPredicting autoimmunity after alemtuzumab treatment of multiple sclerosis
Azzopardi, L., Thompson, S. A. J., Harding, K. E., Cossburn, M., Robertson, N. P., Compston, A., Coles, A. J., & Jones, J. (2013) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2013-307042 · Cited by 50
Self-citationMelzer, N., & Meuth, S. G. (2013) · Clinical & Experimental Immunology · doi:10.1111/cei.12195 · Cited by 50
Dumitriu, B., Ito, S., Feng, X., Stephens, N., Yünce, M., Kajigaya, S., Melenhorst, J. J., Rios, O. J., Scheinberg, P., Chinian, F., et al. (2015) · The Lancet Haematology · doi:10.1016/s2352-3026(15)00227-6 · Cited by 52
Moiola, L., Barcella, V., Benatti, S. V., Capobianco, M. A. N., Capra, R., Cinque, P. M., Comı, G., Fasolo, M., Franzetti, F., Galli, M., et al. (2020) · Multiple Sclerosis Journal · doi:10.1177/1352458520952311 · Cited by 52
What’s new in multiple sclerosis?
Dimitrov, L., & Turner, B. P. (2014) · British Journal of General Practice · doi:10.3399/bjgp14x682609 · Cited by 50
Reen, G., Silber, E., & Langdon, D. W. (2016) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2016.12.038 · Cited by 49
Interferon β-1a and β-1b for patients with multiple sclerosis: updates to current knowledge
Zettl, U. K., Hecker, M., Aktaş, O., Wagner, T. B., & Rommer, P. S. (2018) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2018.1426462 · Cited by 49
CD52 Is a Prognostic Biomarker and Associated With Tumor Microenvironment in Breast Cancer
Wang, J., Zhang, G., Sui, Y., Yang, Z., Chu, Y., Tang, H., Guo, B., Zhang, C., & Wu, C. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.578002 · Cited by 49
Tur, C., Dubessy, A., Otero‐Romero, S., Amato, M. P., Derfuss, T., Pauli, F. D., Iacobaeus, E., Mycko, M. P., Abboud, H., Achiron, A., et al. (2022) · Multiple Sclerosis Journal · doi:10.1177/13524585211069068 · Cited by 50
Self-citationB Cells and Autoantibodies in Multiple Sclerosis
Pröbstel, A., Sanderson, N., & Derfuss, T. J. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160716576 · Cited by 50
Foley, J. F., Stoker, E., & Damal, K. (2013) · Biologics · doi:10.2147/btt.s53007 · Cited by 50
B Cell-Directed Therapeutics in Multiple Sclerosis: Rationale and Clinical Evidence
Häusser‐Kinzel, S., & Weber, M. S. (2016) · CNS Drugs · doi:10.1007/s40263-016-0396-6 · Cited by 49
Zhukovsky, C., Sandgren, S., Silfverberg, T., Einarsdottir, S., Tolf, A., Landtblom, A., Novakova, L., Axelsson, M., Malmeström, C., Cherif, H., et al. (2020) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2020-323992 · Cited by 48
Caon, C., Namey, M., Meyer, C., Mayer, L., Oyuela, P., Margolin, D. H., & Rizzo, M. (2015) · International Journal of MS Care · doi:10.7224/1537-2073.2014-030 · Cited by 47
Self-citationWeetman, A. P. (2014) · Clinical Endocrinology · doi:10.1111/cen.12427 · Cited by 46
Newsome, S. D., Binns, C. C., Kaunzner, U. W., Morgan, S., & Halper, J. (2023) · Neurology and Therapy · doi:10.1007/s40120-023-00549-7 · Cited by 47
Alemtuzumab for multiple sclerosis
Riera, R., Porfírio, G. J., & Torloni, M. R. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011203.pub2 · Cited by 46
Pharmacokinetic evaluation of teriflunomide for the treatment of multiple sclerosis
Wiese, M. D., Rowland, A., Polasek, T. M., Sorich, M. J., & O’Doherty, C. (2013) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2013.800483 · Cited by 47
Prosperini, L., & Pontecorvo, S. (2016) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s85099 · Cited by 47
A Multiple Treatment Comparison of Eleven Disease-Modifying Drugs Used for Multiple Sclerosis
Hamidi, V., Couto, E., Ringerike, T., & Klemp, M. (2017) · Journal of Clinical Medicine Research · doi:10.14740/jocmr3168w · Cited by 44
Thyroid disease and the nervous system
Wood-Allum, C. A., & Shaw, P. J. (2013) · Handbook of clinical neurology · doi:10.1016/b978-0-7020-4087-0.00048-6 · Cited by 45
Multiple sclerosis treatment and infectious issues: update 2013
Winkelmann, A., Loebermann, M., Reisinger, E. C., & Zettl, U. K. (2013) · Clinical & Experimental Immunology · doi:10.1111/cei.12226 · Cited by 45
Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple Sclerosis
Ingwersen, J., Aktaş, O., & Hartung, H. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0412-4 · Cited by 45
Self-citationRotondi, M., Molteni, M., Leporati, P., Capelli, V., Marinò, M., & Chiovato, L. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00254 · Cited by 46
Comparative effectiveness of teriflunomide and dimethyl fumarate
Buron, M. D., Chalmer, T. A., Sellebjerg, F. T., Frederiksen, J. L., Góra, M. K., Illés, Z., Kant, M., Mezei, Z., Petersen, T., Rasmussen, P. V., et al. (2019) · Neurology · doi:10.1212/wnl.0000000000007314 · Cited by 45
Cree, B., Goldman, M. D., Corboy, J. R., Singer, B. A., Fox, E., Arnold, D. L., Ford, C. C., Weinstock‐Guttman, B., Bar‐Or, A., Mientus, S., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.2950 · Cited by 45
Self-citationEffects of Ibudilast on MRI Measures in the Phase 2 SPRINT-MS Study
Naismith, R. T., Bermel, R. A., Coffey, C. S., Goodman, A. D., Fedler, J. K., Kearney, M., Klawiter, E. C., Nakamura, K., Narayanan, S., Goebel, C., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000011314 · Cited by 45
González‐Lorenzo, M., Ridley, B., Minozzi, S., Giovane, C. D., Peryer, G., Piggott, T., Foschi, M., Filippini, G., Tramacere, I., Baldin, E., et al. (2024) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011381.pub3 · Cited by 53
Cheng, Y., Sun, L., Xie, Z., Fan, X., Cao, Q., Han, J., Zhu, J., & Jin, T. (2017) · Journal of Neuroscience Research · doi:10.1002/jnr.24023 · Cited by 45
Fernández, Ó. (2017) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2017.07.003 · Cited by 44
Efficacy and safety of alemtuzumab in a real-life cohort of patients with multiple sclerosis
Frau, J., Coghe, G., Lorefice, L., Fenu, G., Musu, L., & Cocco, E. E. (2019) · Journal of Neurology · doi:10.1007/s00415-019-09272-6 · Cited by 44
Zhang, Y., Caldito, N. G., Shirani, A., Salter, A. R., Cutter, G., Culpepper, W. J., Wallin, M. T., Kosa, P. F., Bielekova, B., LUBLIN, F. D., et al. (2020) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756286420969016 · Cited by 45
Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial
Coles, A. J., Arnold, D. L., Bass, A. D.-D., Boster, A. L., Compston, D. A. S., Fernández, Ó., Havrdová, E., Nakamura, K., Traboulsee, A. L., Ziemssen, T., et al. (2021) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756286420982134 · Cited by 44
Self-citationLycke, J. (2015) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285615605429 · Cited by 43
Lymphocyte pharmacodynamics are not associated with autoimmunity or efficacy after alemtuzumab
Wiendl, H., Carraro, M., Comi, G., Izquierdo, G., Kim, H. J., Sharrack, B., Tornatore, C., Daizadeh, N. S., Chung, L. E., Jacobs, A. K., et al. (2019) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000635 · Cited by 43
Gehr, S., Kaiser, T., Kreutz, R. H., Ludwig, W.-D., & Paul, F. (2019) · The EPMA Journal · doi:10.1007/s13167-019-00192-z · Cited by 43
Novel Agents for Relapsing Forms of Multiple Sclerosis
Farber, R. S., Harel, A., & LUBLIN, F. D. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-052814-023415 · Cited by 42
Hettle, R., Harty, G. T., & Wong, S. L. (2018) · Journal of Medical Economics · doi:10.1080/13696998.2018.1461630 · Cited by 42
Escalation vs. Early Intense Therapy in Multiple Sclerosis
Casanova, B., Quintanilla‐Bordás, C., & Gascón, F. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12010119 · Cited by 46
Daclizumab (anti-CD25) in multiple sclerosis
Pfender, N., & Martinꝉ, R. (2014) · Experimental Neurology · doi:10.1016/j.expneurol.2014.04.015 · Cited by 44
Śladowska, K., Kawalec, P., Holko, P., & Osiecka, O. (2022) · Neurological Sciences · doi:10.1007/s10072-022-06197-3 · Cited by 45
Olejnik, P., Roszkowska, Z., Adamus, S., & Kasarełło, K. (2024) · Pharmacological Reports · doi:10.1007/s43440-024-00642-0 · Cited by 49
De-escalating and discontinuing disease-modifying therapies in multiple sclerosis
Androdias, G., Lünemann, J. D., Maillart, É., Amato, M. P., Audoin, B., Bruijstens, A. L., Bsteh, G., Butzkueven, H., Ciccarelli, O., Cobo‐Calvo, Á., et al. (2024) · Brain · doi:10.1093/brain/awae409 · Cited by 41
Self-citationAlemtuzumab: A Review in Relapsing Remitting Multiple Sclerosis
Syed, Y. Y. (2020) · Drugs · doi:10.1007/s40265-020-01437-2 · Cited by 40
Gaj, S., Ontaneda, D., & Nakamura, K. (2021) · PLoS ONE · doi:10.1371/journal.pone.0255939 · Cited by 42
Singer, B. A., Feng, J. J., & Chiong-Rivero, H. (2024) · Journal of Neurology · doi:10.1007/s00415-024-12305-4 · Cited by 43
What's new in multiple sclerosis?
Tillery, E. E., Clements, J. N., & Howard, Z. (2017) · Mental Health Clinician · doi:10.9740/mhc.2017.09.213 · Cited by 42
Riepl, E., Pfeuffer, S., Ruck, T., Lohmann, H., Wiendl, H., Meuth, S. G., & Johnen, A. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2017.00730 · Cited by 39
New drugs for multiple sclerosis: new treatment algorithms
Cree, B., Hartung, H., & Barnett, M. H. (2022) · Current Opinion in Neurology · doi:10.1097/wco.0000000000001063 · Cited by 41
Self-citationThe efficacy and safety of daclizumab and its potential role in the treatment of multiple sclerosis
Milo, R. (2014) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285613504021 · Cited by 38
Multiple Sclerosis Outcome Assessments Consortium: Genesis and initial project plan
Rudick, R. A., LaRocca, N. G., Hudson, L. D., & MSOAC (2013) · Multiple Sclerosis Journal · doi:10.1177/1352458513503392 · Cited by 38
Pasquier, R. D., Pinschewer, D. D., & Merkler, D. (2014) · CNS Drugs · doi:10.1007/s40263-014-0160-8 · Cited by 42
Current and Future Therapies Targeting the Immune System in Multiple Sclerosis
Loleit, V., Biberacher, V., & Hemmer, B. (2014) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201015666140617104332 · Cited by 37
Belogurov, A. A., Анатольевич, З. К., Lomakin, Y. A., Surkov, K. G., Avtushenko, S., Kruglyakov, P. V., Smirnov, I. V., Сергеевич, М. Г., Lockshin, C., Gregoriadis, G., et al. (2016) · Neurotherapeutics · doi:10.1007/s13311-016-0448-0 · Cited by 38
Safety of monoclonal antibodies for the treatment of multiple sclerosis
McGinley, M., Moss, B. P., & Cohen, J. A. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1250881 · Cited by 37
Self-citationImpact of Desensitization on Antiviral Immunity in HLA-Sensitized Kidney Transplant Recipients
Toyoda, M., Shin, B., Ge, S., Mirocha, J., Thomas, D., Chu, M., Rodriguez, E., Chao, C., Petrosyan, A., Galera, O. A., et al. (2017) · Journal of Immunology Research · doi:10.1155/2017/5672523 · Cited by 38
Modulating inflammation and neuroprotection in multiple sclerosis
Yong, H. Y. F., Chartier, G., & Quandt, J. A. (2017) · Journal of Neuroscience Research · doi:10.1002/jnr.24090 · Cited by 39
Decallonne, B., Bartholome, E. J., Delvaux, V., D’haeseleer, M., Sankari, S. E., Seeldrayers, P., Wijmeersch, B. V., & Daumerie, C. (2018) · Acta Neurologica Belgica · doi:10.1007/s13760-018-0883-2 · Cited by 41
Effects of disease-modifying therapy on peripheral leukocytes in patients with multiple sclerosis
Schweitzer, F., Laurent, S. A., Fink, G. R., Barnett, M. H., Hartung, H., & Warnke, C. (2020) · Journal of Neurology · doi:10.1007/s00415-019-09690-6 · Cited by 40
Self-citationaHSCT is superior to alemtuzumab in maintaining NEDA and improving cognition in multiple sclerosis
Häußler, V., Ufer, F., Pöttgen, J., Wolschke, C., Friese, M. A., Kröger, N., Heesen, C., & Stellmann, J. (2021) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51366 · Cited by 38
Induction Therapy for Patients with Multiple Sclerosis: Why? When? How?
Edan, G., & Page, E. L. (2013) · CNS Drugs · doi:10.1007/s40263-013-0065-y · Cited by 38
TONiC Study Group, Pomeroy, I. M., Tennant, A., Mills, R. J., & Young, C. A. (2020) · Quality of Life Research · doi:10.1007/s11136-020-02463-z · Cited by 36
Oh, J., Achiron, A., Celius, E. G., Chambers, C., Derwenskus, J., Devonshire, V. A., Hellwig, K., Hutton, G. J., McCombe, P., Moore, M., et al. (2020) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2020.102146 · Cited by 37
Self-citationKühle, J., Daizadeh, N. S., Benkert, P., Maceski, A. M., Barro, C., Michalak, Z., Sormani, M. P., Godin, J., Shankara, S., Samad, T. A., et al. (2021) · Multiple Sclerosis Journal · doi:10.1177/13524585211032348 · Cited by 37
Advances in the treatment of relapsing - Remitting multiple sclerosis
Constantinescu, C. S., Tănăsescu, R., Ionete, C., & Chou, I. (2014) · Biomedical Journal · doi:10.4103/2319-4170.130440 · Cited by 38
Metadata
- Authors
- Cohen, J. A., Coles, A. J., Arnold, D. L., Confavreux, C., Fox, E. J., Hartung, H.-P., Havrdova, E., Selmaj, K. W., Weiner, H. L., Fisher, E., Brinar, V. V., Giovannoni, G., Stojanovic, M., Ertik, B. I., Lake, S. L., Margolin, D. H., Panzara, M. A., & Compston, D. A. S.
- Affiliations
- Cleveland Clinic (US)
- University of Cambridge (GB)
- Montreal Neurological Institute and Hospital (CA)
- Lyon 1 Université (FR)
- Central Texas Neurology Consultants (US)
- Heinrich Heine University Düsseldorf (DE)
- Medical University of Lodz (PL)
- Brigham and Women's Hospital (US)
- University Hospital Centre Zagreb (HR)
- Queen Mary University of London (GB)
- Clinical Centre of Kragujevac (RS)
- Corresponding author
- Cohen, Jeffrey A
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2012-11
- Volume
- 380
- Issue
- 9856
- Pages
- 1819-1828
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2148766438
- Cited by
- 1,205
- References
- 39
- Citations by year
- 2026: 25 · 2025: 52 · 2024: 66 · 2023: 71 · 2022: 70 · 2021: 77 · 2020: 109 · 2019: 112 · 2018: 108 · 2017: 120 · 2016: 112 · 2015: 104 · 2014: 85 · 2013: 83 · 2012: 6
- FWCI
- 64.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- Digital Academic REpository of VU University Amsterdam (Vrije Universiteit Amsterdam) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- National Institute for Health and Care Research (NF-SI-0508-10335)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Oncology › Polyomavirus and related diseases
- Keywords
- alemtuzumab, interferon beta-1a, relapsing-remitting multiple sclerosis, first-line therapy, anti-CD52 monoclonal antibody, relapse rate, disability progression, disease-modifying therapy, treatment safety, treatment-naive patients, relapse-free survival, time to treatment discontinuation, adverse events, immunosuppression
- MeSH terms
- Interferon beta-1a, Alemtuzumab, Adjuvants, Immunologic, Administration, Cutaneous, Adolescent, Adult, Female, Humans, Infusions, Intravenous, Male, Middle Aged, Recurrence, Treatment Outcome, Interferon-beta, Disease-Free Survival, Multiple Sclerosis, Relapsing-Remitting, Kaplan-Meier Estimate, Young Adult, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
